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S U M M A R Y
Background: Congenital cytomegalovirus (CMV) infection is the leading infectious cause of congenital
hearing loss and neurodevelopmental disability in developed countries. Information on congenital CMV
infection in developing countries appears to be lacking.
Methods: We conducted a systematic literature review to identify studies from developing countries
with population-based samples of at least 300 infants that used laboratory methods established as
reliable for the diagnosis of congenital CMV infection.
Results: Most studies were excluded due to biased samples or inadequate diagnostic methods;
consequently the search identiﬁed just 11 studies that were from Africa, Asia, and Latin America. The
number of newborns tested ranged from 317 to 12 195. Maternal CMV seroprevalence ranged from 84%
to 100%. CMV birth prevalence varied from 0.6% to 6.1%. CMV-associated impairments were not
documented in most studies.
Conclusions: Birth prevalence ranges were higher than for Europe and North America, as expected based
on the higher maternal CMV seroprevalence. With very limited data available on sequelae, the disease
burden of congenital CMV in developing countries remains largely unknown at this time.
Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
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Open access under CC BY-NC-ND license.1. Introduction
Human cytomegalovirus (CMV) is a member of the herpesvirus
family and one of the most ubiquitous viruses in humans.
Congenital CMV infection occurs when virus from the mother
crosses the placenta and infects the immunologically immature
fetus. The consequences or sequelae of congenital CMV infection
include fetal death, infant death, and neurological and sensory
impairments.1,2 During pregnancy, women may have either a
primary (ﬁrst) CMV infection or non-primary infection, in which a
previously infected woman experiences reactivation of a latent
virus or re-infection with a new viral strain. The frequency of
vertical transmission and severity of the outcome is reported to be
much greater for primary maternal infection;3 however, non-§§ Disclaimer: The ﬁndings and conclusions in this article are those of the authors
and do not necessarily represent the ofﬁcial position of the Centers for Disease
Control and Prevention.
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http://dx.doi.org/10.1016/j.ijid.2013.12.010primary infection is more common than primary infections and
thus likely contributes more total cases of congenital CMV
infection and related disability.4–6
The prevalence of congenital CMV infection has been reported
to vary from approximately 0.2% to 2% (average 0.65%), with higher
overall rates in countries with higher maternal seroprevalence.7,8
Most of these estimates come from studies conducted in Europe,
the USA, and Japan. In developing countries, the reported
prevalence of congenital CMV infection varies substantially, both
within and between countries, with some reported prevalences as
high as 6–14%.9,10 Higher birth prevalences combined with
additional stresses on infant health in developing countries could
augment disability from congenital CMV infection. We conducted a
systematic review of the literature to identify population-based
studies from developing countries that evaluated congenital CMV
infection birth prevalence, and where available sequelae, using
methods that are considered reliable for the evaluation of
congenital CMV infection.
2. Methods
We identiﬁed studies published prior to May 2013 that
reported the birth prevalence of congenital CMV infection byiseases. Open access under CC BY-NC-ND license.
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BioMed Central, and CABDirect databases using the keywords
CMV, HCMV, cytomegalovirus, human cytomegalovirus, congeni-
tal, infant, neonate, newborn, incidence, and prevalence, with no
restrictions on language. We restricted the search to articles from
countries in Africa, the Americas, Caribbean Region, Central
America, Latin America, South America, Asia, Atlantic Islands,
and Indian Ocean Islands. We excluded articles from the USA,
Canada, Japan, Australia, and Europe, and articles focused on HIV
infection. Articles were ﬂagged if the title or abstract indicated that
the study reported the birth prevalence of congenital CMV
infection in countries classiﬁed as developing by the International
Monetary Fund.11 Two studies were included that were from
countries currently not categorized as developing, but which were
considered developing when the studies were conducted (Taiwan
1996; Republic of Korea 1992).11 We also reviewed citations in the
articles from our search to identify any additional relevant articles
not captured by the database searches. We reviewed titles and
abstracts from the resulting group of citations and selected articles
that reported the birth prevalence of CMV.
Among selected articles, we reviewed the full text to identify
studies meeting the following criteria: original peer-reviewed
studies with either a cohort or cross-sectional design, a popula-
tion-based sample of at least 300 newborns, diagnosis of
congenital CMV infection by detection of virus by culture or viral
DNA by PCR from infant urine or saliva collected within 3 weeks of
birth.12,13
We excluded studies using CMV IgM-based screening because
of the low sensitivity of IgM for the detection of congenital
infection14,15 and highly variable performance among commercial
tests.16,17 In the case of multiple reports from the same authors
with overlapping study dates, we included the most recent or most
comprehensive report. We excluded studies limited to maternal
populations with an elevated risk of transmitting congenital CMV
infection, such as mothers with recent primary CMV infection or
HIV infection. We also excluded studies with infant populationsTable 1
Summary of methods and results from studies assessing birth prevalence of congenita
First author and
year of publication
Country and
time period
Maternal
seroprevalence
Newborn screening 
Clinical specimens La
Schopfer
197819
Ivory Coast
-
100% Urine Cu
van der Sande
200720
Gambiaa
2002–2005
100%b Urine PC
Sohn
199221
Korea
1989–1991
96%b Urine and cord blood Cu
Tsai
199622
Taiwana
-
90% Urine Cu
Zhang
200710
China
1997–2000
92–99% Urine PC
Dar
200823
India
-
99%b Saliva, urinec PC
Luchsinger
199624
Chile
1989–1994
98% Urine and saliva Cu
Weirich
199725
Brazil
1994–1995
90%b Saliva Cu
Yamamoto
201126
Brazil
2003–2009
96% Urine and/or saliva PC
Noyola
200327
Mexicoa
2001
92% Saliva Cu
Estripeaut
200728
Panama
2003–2004
84%b Urine PC
CMV, cytomegalovirus; CI, conﬁdence interval.
a Studies that were conducted in well-baby nurseries or excluded severely ill newbo
b Mothers tested as part of the study.
c Indicates specimen or method used for conﬁrmation.selected for clinical signs of congenital CMV infection or
hospitalization in neonatal intensive care units.
For each of the studies that met the above criteria we extracted
the following information: maternal demographics and CMV
seroprevalence; methods used for CMV newborn screening (types
of clinical specimen, time to specimen collection following birth,
laboratory methods); number of newborns tested for and positive
for congenital CMV infection; number of congenitally infected
newborns who were symptomatic at birth, as assessed by the
individual studies since criteria for deﬁning symptomatic congen-
ital CMV disease varied across studies and in some studies was not
deﬁned. The quality of individual studies was assessed by
evaluating sample size, risk of bias in the study population, and
the laboratory methods. We calculated the conﬁdence intervals for
the birth prevalence estimates and, to assess the heterogeneity
across the studies, we calculated the I2 statistic, which indicates
the proportion of total variation across studies that is due to
heterogeneity (e.g., likely to arise from true differences in
prevalence, study quality, inclusion criteria, laboratory methods)
rather than chance.18 Analyses were performed using Compre-
hensive Meta Analysis Version 2.2.064 (Biostat, Englewood, NJ,
USA).
3. Results
Of a total of 564 citations identiﬁed, 84 met criteria for full-text
assessment, of which 11 met criteria for inclusion in this review. Of
the 73 studies excluded after full-text assessment, 55 (46%) had a
sample size less than 300 newborns, 52 (44%) had biased
populations that over-represented mothers with primary CMV
infection or symptomatic newborns, and 34 (29%) used exclusively
CMV IgM-based screening; 44 (71%) were excluded for more than
one of the above reasons. Of the 11 studies included in this review,
two were conducted in Africa (Ivory Coast19 and Gambia20), four in
Asia (Korea,21 Taiwan,22 China,10 and India23), and ﬁve in Latin
America (Chile,24 Brazil,25,26 Mexico,27 and Panama28) (Table 1).l CMV infection in developing countries
Number of newborns with congenital CMV (%)
boratory methods Tested Infected Symptomatic
n Prevalence, % (95% CI)
lture 2032 28 1.4 (1.0–2.0) 0 (0)
R 741 40 5.4 (4.0–7.3) 3 (8)
lture 514 6 1.2 (0.5–2.6) 0 (0)
lture, PCR 1000 18 1.8 (1.1–2.8) 2 (11)
R 1159 71 6.1 (4.9–7.7) 17 (24)
R 423 9 2.1 (1.1–4.0) 1 (11)
lture, PCR 658 12 1.8 (1.0–3.2) 0 (0)
lture 663 21 3.2 (2.1–4.8) 6 (29)
R, culturec 12 195 121 1.0 (0.8–1.2) 12 (10)
lture 560 5 0.9 (0.4–2.1) 0 (0)
R 317 2 0.6 (0.2–2.5) 1 (50)
rns.
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and one in 1978. The duration of enrollment for the studies varied
from 3 months to 6 years. Four were cross-sectional studies and
seven were cohort studies.
The number of newborns tested for congenital CMV infection
varied from 317 to 12 195; seven out of 11 studies had <1000
newborns tested. Three of the 11 studies excluded some categories
of ill newborns from screening: the study from Gambia excluded
newborns that were preterm or had serious congenital deﬁcits; the
study from Taiwan screened only newborns who were ‘essentially
healthy’ at birth; and the study from Mexico was limited to
newborns from the well-baby nursery. Clinical specimens were
collected within 3 days of birth in nine studies and within 1 or 2
weeks of birth in the remaining studies. Five studies relied
exclusively on PCR for the detection of CMV. Our quality
assessment indicated a high risk of bias for all studies except for
the Yamamoto study from Brazil.26
The birth prevalence of congenital CMV infection varied from
0.6% in Panama to 6.1% in China (Table 1). The I2 value was 95%,
indicating considerable heterogeneity across the studies, therefore
we did not combine the studies to estimate an average birth
prevalence of congenital CMV infection.
Criteria used to deﬁne infected newborns as symptomatic
varied across studies. All newborns with congenital CMV infection
received a physical examination at birth. More thorough assess-
ment with head imaging, audiological, ophthalmological, and/or
neurological examinations was performed in three studies.22,26,28
The proportion of newborns with congenital CMV infection
classiﬁed as symptomatic at birth in studies with >15 infected
newborns varied from 0% in four of the studies19,21,24,27 to 29% in
the Weirich study from Brazil.25 Studies conducted in Mexico and
Gambia that excluded some categories of ill infants reported 8–11%
of infected newborns had symptomatic infection.20,27 The Yama-
moto study from Brazil included a precise case deﬁnition of
symptomatic congenital CMV disease based on the presence of at
least one of the following: petechiae, cholestatic jaundice
(conjugated bilirubin level>2 mg/dl), hepatosplenomegaly, pur-
pura, microcephaly, seizures, chorioretinitis, or abnormal cranial
computerized tomography (CT) ﬁndings.26 In that study, 12 (10%)
of 121 newborns with congenital CMV infection were classiﬁed as
symptomatic, three of whom had only abnormal cranial CT
ﬁndings. However, the proportion of symptomatic infants would
have increased to 22% if intrauterine growth restriction had also
been included as a criterion of symptomatic congenital CMV
disease, which it often is.
All studies reported maternal seroprevalence 90%, except the
study from Panama in which maternal seroprevalence was 84%;
mothers were tested directly for CMV IgG antibody in ﬁve
studies.20,21,23,25,28 Among six studies that reported maternal
demographic information, mothers of infected newborns were
younger20,21,24,25,27 and more likely to be primigravidae or
primiparae20,24,27,28 than mothers of uninfected newborns. In
the study from India, the median number of children among
mothers of infected newborns was one (range one to two)
compared to two (range one to six) among mothers of uninfected
newborns.23 In contrast, the study from Ivory Coast reported
similar distributions of maternal age and parity for newborns with
and without congenital CMV infection.19
4. Discussion
Our systematic review of the literature on congenital CMV
infection in developing countries identiﬁed 11 population-based
studies using laboratory methods that are established as reliable
for identifying congenital CMV infection. The CMV birth rates
ranged from 0.6% to 6.1%, which is higher than the range of0.2–2.0% (average of 0.65%) most often reported for developed
countries,7,8 although the extent to which the selected studies are
representative of other developing countries is not known. More
studies are needed to understand the burden of disease associated
with congenital CMV infection in these populations and how it
may be affected by other prevalent conditions such as HIV
infection, malnutrition, and malaria.
We found substantial variability across studies in the criteria
used to deﬁne symptomatic congenital CMV infection, which is the
main recognized predictor of permanent sequelae from CMV
infection.8 Based on data from developed countries, an estimated
40–58% of newborns with symptomatic congenital CMV infection
at birth will have permanent neurodevelopmental disabilities.8 Of
studies we reviewed that had at least 15 infants with congenital
CMV infection, the proportion classiﬁed as symptomatic was 0–
29%, which is similar to estimates of 5–20% from studies in
developed countries.8 Some of the criteria used to identify
symptomatic CMV infection may be problematic when applied
to developing countries. For example, intrauterine growth
retardation is often associated with congenital CMV,2,29,30 but it
is more common and less speciﬁc to CMV in developing countries
given its association with maternal socioeconomic and nutritional
factors, chronic diseases, and the use of drugs.31 Abnormal cranial
CT ﬁndings are associated with congenital CMV infection and long-
term sequelae,32 but CT scans cannot be performed routinely in
limited-resource settings, and infants with congenital CMV
infection presenting with central nervous system involvement
may be more likely to remain undiagnosed in the newborn period.
Conditions for specimen collection, processing, and testing can
be suboptimal in developing countries and cause laboratory results
to be less accurate. Two reports with the highest rates of congenital
CMV infection (5.4% in Gambia20 and 6.1% in China10) relied
exclusively on PCR methods. Other reports using PCR that did not
meet our inclusion criteria reported higher CMV birth prevalences
of 10–20%. Due to the extreme sensitivity of diagnostic PCR, false-
positive results can occur in laboratories that do not have extensive
expertise and quality control33 and may result in artiﬁcially high
estimates of CMV birth prevalence. High quality diagnostics also
rely on specimen transport and storage at cold temperatures that
are harder to maintain in areas with weaker infrastructure and
inconsistent power supplies.
Findings from the countries included in our review are not
necessarily representative of that country or region. The results
from Gambia and Ivory Coast may not be generalizable to other
regions in Africa with signiﬁcantly different HIV prevalence, since
CMV is more readily transmitted in the setting of HIV infection.34,35
Also, ﬁve of the studies were conducted two decades or longer ago
and it is likely that living conditions have since changed. High
seroprevalence is associated with lower socioeconomic status and
crowding, which may have increased or decreased in some regions,
altering patterns of CMV infection. This is especially true with very
large, socioeconomically dynamic countries like China, India, and
Brazil, where birth prevalences may vary substantially from region
to region and by sociodemographic characteristics. A study from
1985 by Pannuti et al.36 screened two groups of approximately 500
newborns for CMV by viral culture with results similar to other
studies. The Pannuti study was not included in our analysis to
avoid over-representation of any given population, because their
sample was from the same region of Brazil as the 2011 study by
Yamamoto26 with 12 195 newborns screened.
CMV seroprevalence in developing countries is generally over
90% by adolescence and over 95% by early adulthood. Consequently
most cases of congenital CMV infection result from non-primary
maternal infection. By comparison, the CMV seroprevalence among
12–40-year-olds is 40–60% in the USA,37 where both primary
and non-primary maternal infection contribute substantially to
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tions due to primary vs. non-primary maternal infection from one
another is not easily done. Studying congenital CMV infection in
regions with very high seroprevalence presents the opportunity to
study outcomes in a population in which those are likely due almost
entirely to non-primary infection. A meta-analysis by de Vries et al.
reported that the pooled risk of hearing loss from seven studies
conducted in Europe and the Americas was similar following
primary or non-primary maternal CMV infection.6 In a study from
Brazil, the frequency of hearing loss was reported to be 33% (1/3)
following primary infection, 15% following non-primary infection
(6/40), and 7% (3/42) for indeterminate infections.26Overall, 6% of 85
infected infants followed up for at least 12 months were diagnosed
with bilateral moderate to profound sensorineural hearing loss.26
The ﬁndings from Brazil suggest that the frequency of bilateral
moderate to profound sensorineural hearing loss is similar to or
higher than in high-income countries (3–5%),38 despite a shorter
length of follow-up in the Brazilian study. In general, data on the
association of non-primary infections with outcomes of congenital
CMV infection are lacking.
CMV-associated sequelae could potentially be augmented by
other perinatal conditions common in developing countries, such
as malnutrition, malaria, and other infections, especially HIV.
These factors contribute to higher rates of prematurity and
intrauterine growth restriction, which have an impact on neonatal
mortality and long-term morbidity.39 The study from Gambia
included in our review found that the prevalence of congenital
CMV infection was three-fold higher among infants born to
mothers who had acute placental malaria infection.20 Studies have
shown that maternal HIV infection may increase the risk of vertical
transmission of CMV, symptomatic disease, and long-term
sequelae in infected infants, thus high HIV prevalence increases
the overall burden of congenital CMV infection.34,35,40,41 In
addition, adolescent pregnancy is more common in many
developing countries and young maternal age is an established
risk factor for congenital CMV infection. In this review, the
association with young maternal age was present in ﬁve of six
studies that recorded maternal age.
Our review has several limitations, the main one being the
small number of papers that have been published on this subject.
We observed a wide prevalence range across countries (0.6% in
Panama28 to 6.1% in China10) that could have resulted as much
from different methods as from true differences in population
prevalence. We made every attempt to identify studies that
applied unselected or random screening of newborns, but many
studies lacked clear descriptions of their study populations. Three
of 11 studies either excluded infants who were ‘seriously ill’ or
limited screening to the well-baby nursery, which could have
caused an underestimate of CMV birth prevalence in those studies.
In conclusion, developing countries have some of the world’s
largest populations and highest birth rates, thus the aggregate
number of children born with congenital CMV infection in these
regions is likely to be enormous. Most congenital CMV infection in
developing countries results from non-primary maternal infection,
which is less understood as a cause of congenital CMV disease than
primary maternal infection. The potential for vaccines and
behavioral interventions42 to reduce non-primary infection and
the associated burden of disease is unknown. There is especially a
need for research on the potential for other health stresses in
developing countries to augment mortality and morbidity of
congenital CMV infection. Studies that test unselected populations
of newborns for CMV using established methods, and that evaluate
the infants at birth and for at least a few years after birth, may not
be feasible in many developing countries, but could be a goal if and
when resources become available. At the present time no effective
interventions to interrupt the transmission of congenital CMV canbe recommended for such populations, however, clinicians should
be aware of both the ubiquity and risk of CMV infection in
pregnancy.
Funding source: No external funding was used for this study.
Conﬂict of interest: The authors have no conﬂicts of interest.
References
1. Enders G, Bader U, Lindemann L, Schalasta G, Daiminger A. Prenatal diagnosis of
congenital cytomegalovirus infection in 189 pregnancies with known outcome.
Prenat Diagn 2001;21:362–77.
2. Boppana SB, Pass RF, Britt WJ, Stagno S, Alford CA. Symptomatic congenital
cytomegalovirus infection: neonatal morbidity and mortality. Pediatr Infect Dis J
1992;11:93–9.
3. Fowler KB, Stagno S, Pass RF, Britt WJ, Boll TJ, Alford CA. The outcome of
congenital cytomegalovirus infection in relation to maternal antibody status. N
Engl J Med 1992;326:663–7.
4. Wang C, Zhang X, Bialek S, Cannon MJ. Attribution of congenital cytomegalovi-
rus infection to primary versus non-primary maternal infection. Clin Infect Dis
2011;52:e11–3.
5. Mussi-Pinhata MM, Yamamoto AY, Moura Brito RM, de Lima Isaac M, de
Carvalho e Oliveira PF, Boppana S, et al. Birth prevalence and natural history
of congenital cytomegalovirus infection in a highly seroimmune population.
Clin Infect Dis 2009;49:522–8.
6. de Vries JJ, van Zwet EW, Dekker FW, Kroes AC, Verkerk PH, Vossen AC. The
apparent paradox of maternal seropositivity as a risk factor for congenital
cytomegalovirus infection: a population-based prediction model. Rev Med Virol
2013;23:241–9.
7. Kenneson A, Cannon MJ. Review and meta-analysis of the epidemiology of
congenital cytomegalovirus (CMV) infection. Rev Med Virol 2007;17:253–76.
8. Dollard SC, Grosse SD, Ross DS. New estimates of the prevalence of neurological
and sensory sequelae and mortality associated with congenital cytomegalovi-
rus infection. Rev Med Virol 2007;17:355–63.
9. Bello C, Whittle H. Cytomegalovirus infection in Gambian mothers and their
babies. J Clin Pathol 1991;44:366–9.
10. Zhang XW, Li F, Yu XW, Shi XW, Shi J, Zhang JP. Physical and intellectual
development in children with asymptomatic congenital cytomegalovirus in-
fection: a longitudinal cohort study in Qinba mountain area, China. J Clin Virol
2007;40:180–5.
11. Nielsen L. Classiﬁcations of countries based on their level of development: how
it is done and how it could be done. International Monetary Fund Working
Paper. Washington, DC: IMF; 2011.
12. Revello MG, Gerna G. Diagnosis and management of human cytomegalovirus
infection in the mother, fetus, and newborn infant. Clin Microbiol Rev
2002;15:680–715.
13. Lazzarotto T, Guerra B, Lanari M, Gabrielli L, Landini MP. New advances in the
diagnosis of congenital cytomegalovirus infection. J Clin Virol 2008;41:192–7.
14. Stagno S, Tinker MK, Elrod C, Fuccillo DA, Cloud G, O’Beirne AJ. Immunoglobulin
M antibodies detected by enzyme-linked immunosorbent assay and radioim-
munoassay in the diagnosis of cytomegalovirus infections in pregnant women
and newborn infants. J Clin Microbiol 1985;21:930–5.
15. Halwachs-Baumann G, Genser B, Danda M, Engele H, Rosegger H, Folsch B, et al.
Screening and diagnosis of congenital cytomegalovirus infection: a 5-y study.
Scand J Infect Dis 2000;32:137–42.
16. Lazzarotto T, Galli C, Pulvirenti R, Rescaldani R, Vezzo R, La Gioia A, et al.
Evaluation of the Abbott AxSYM cytomegalovirus (CMV) immunoglobulin M
(IgM) assay in conjunction with other CMV IgM tests and a CMV IgG avidity
assay. Clin Diagn Lab Immunol 2001;8:196–8.
17. Gentile M, Galli C, Pagnotti P, Di Marco P, Tzantzoglou S, Bellomi F, et al.
Measurement of the sensitivity of different commercial assays in the diagnosis
of CMV infection in pregnancy. Eur J C Microbiol Infect Dis 2009;28:977–81.
18. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in
meta-analyses. BMJ 2003;327:557–60.
19. Schopfer K, Lauber E, Krech U. Congenital cytomegalovirus infection in new-
born infants of mothers infected before pregnancy. Arch Dis Child 1978;53:
536–9.
20. van der Sande MA, Kaye S, Miles DJ, Waight P, Jeffries DJ, Ojuola OO, et al. Risk
factors for and clinical outcome of congenital cytomegalovirus infection in a
peri-urban West-African birth cohort. PLoS One 2007;2:e492.
21. Sohn YM, Park KI, Lee C, Han DG, Lee WY. Congenital cytomegalovirus infection
in Korean population with very high prevalence of maternal immunity. J Korean
Med Sci 1992;7:47–51.
22. Tsai CH, Tsai FJ, Shih YT, Wu SF, Liu SC, Tseng YH. Detection of congenital
cytomegalovirus infection in Chinese newborn infants using polymerase chain
reaction. Acta Paediatr 1996;85:1241–3.
23. Dar L, Pati SK, Patro AR, Deorari AK, Rai S, Kant S, et al. Congenital cytomegalo-
virus infection in a highly seropositive semi-urban population in India. Pediatr
Infect Dis J 2008;27:841–3.
24. Luchsinger V, Suarez M, Schultz R, Barraza P, Guzman M, Terrada L, et al.
[Incidence of congenital cytomegalovirus infection in newborn infants of
different socioeconomic strata]. Rev Med Chil 1996;124:403–8.
25. Weirich J. [Congenital cytomegalovirus infection: a study carried out in the
‘‘Fundacao Santa Casa de Misericordia do Para’’, Brazil]. Rev Soc Bras Med Trop
1998;31:325–6.
T.M. Lanzieri et al. / International Journal of Infectious Diseases 22 (2014) 44–484826. Yamamoto AY, Mussi-Pinhata MM, Isaac Mde L, Amaral FR, Carvalheiro CG,
Aragon DC, et al. Congenital cytomegalovirus infection as a cause of sensorineural
hearing loss in a highly immune population. Pediatr Infect Dis J 2011;30:1043–6.
27. Noyola DE, Mejia-Elizondo AR, Canseco-Lima JM, Allende-Carrera R, Hernan-
sez-Salinas AE, Ramirez-Zacarias JL. Congenital cytomegalovirus infection in
San Luis Potosi, Mexico. Pediatr Infect Dis J 2003;22:89–90.
28. Estripeaut D, Moreno Y, Ahumada Ruiz S, Martinez A, Racine JD, Saez-Llorens X.
[Seroprevalence of cytomegalovirus infection in puerperal women and its
impact on their newborns]. An Pediatr (Barc) 2007;66:135–9.
29. Istas AS, Demmler GJ, Dobbins JG, Stewart JA. Surveillance for congenital
cytomegalovirus disease: a report from the National Congenital Cytomegalo-
virus Disease Registry. Clin Infect Dis 1995;20:665–70.
30. Williamson WD, Demmler GJ, Percy AK, Catlin FI. Progressive hearing loss in
infants with asymptomatic congenital cytomegalovirus infection. Pediatrics
1992;90:862–6.
31. Sheridan C. Intrauterine growth restriction—diagnosis and management. Aust
Fam Physician 2005;34:717–23.
32. Noyola DE, Demmler GJ, Nelson CT, Griesser C, Williamson WD, Atkins JT, et al.,
Houston Congenital CMV Longitudinal Study Group. Early predictors of neu-
rodevelopmental outcome in symptomatic congenital cytomegalovirus infec-
tion. J Pediatr 2001;138:325–31.
33. Espy MJ, Uhl JR, Sloan LM, Buckwalter SP, Jones MF, Vetter EA, et al. Real-time
PCR in clinical microbiology: applications for routine laboratory testing. Clin
Microbiol Rev 2006;19:165–256.
34. Doyle M, Atkins JT, Rivera-Matos IR. Congenital cytomegalovirus infection in
infants infected with human immunodeﬁciency virus type 1. Pediatr Infect Dis J
1996;15:1102–6.35. Guibert G, Warszawski J, Le Chenadec J, Blanche S, Benmebarek Y, Mandelbrot L,
et al., French Perinatal Cohort. Decreased risk of congenital cytomegalovirus
infection in children born to HIV-1-infected mothers in the era of highly active
antiretroviral therapy. Clin Infect Dis 2009;48:1516–25.
36. Pannuti CS, Vilas-Boas LS, Angelo MJ, Carvalho RP, Segre CM. Congenital
cytomegalovirus infection. Occurrence in two socioeconomically distinct
populations of a developing country. Rev Inst Med Trop Sao Paulo 1985;27:
105–7.
37. Bate SL, Dollard SC, Cannon MJ. Cytomegalovirus seroprevalence in the United
States: the national health and nutrition examination surveys, 1988-2004. Clin
Infect Dis 2010;50:1439–47.
38. Grosse SD, Ross DS, Dollard SC. Congenital cytomegalovirus (CMV) infection as
a cause of permanent bilateral hearing loss: a quantitative assessment. J Clin
Virol 2008;41:57–62.
39. Moss W, Darmstadt GL, Marsh DR, Black RE, Santosham M. Research priorities
for the reduction of perinatal and neonatal morbidity and mortality in devel-
oping country communities. J Perinatol 2002;22:484–95.
40. Manicklal S, Emery VC, Lazzarotto T, Boppana SB, Gupta RK. The ‘‘silent’’
global burden of congenital cytomegalovirus. Clin Microbiol Rev 2013;26:
86–102.
41. Slyker JA, Lohman-Payne BL, John-Stewart GC, Maleche-Obimbo E, Emery S,
Richardson B, et al. Acute cytomegalovirus infection in Kenyan HIV-infected
infants. AIDS 2009;23:2173–81.
42. Vauloup-Fellous C, Picone O, Cordier AG, Parent-du-Chatelet I, Senat MV,
Frydman R, et al. Does hygiene counseling have an impact on the rate of
CMV primary infection during pregnancy? Results of a 3-year prospective
study in a French hospital. J Clin Virol 2009;46(Suppl 4):S49–53.
